#2024-1238Decree No. 2024-1238 on Protecting Workers from Ionizing Radiation Risks
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This law aims to protect workers from risks associated with ionizing radiation. It updates existing regulations to ensure greater safety in workplaces where such risks are present. Key changes include adjusting the monitoring and reporting mechanisms for radiation exposure and revising the responsibilities of employers concerning worker safety.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Revised exposure monitoring guidelines
- Introduced new reporting mechanisms
- Redefined employer responsibilities in worker safety
Obligations
What this law requires
Employers must delimit a 'radiological safety zone' around orphaned radioactive sources or radioactive substance pollution requiring decontamination, ensuring dose equivalent rate remains below 0.5 microsievert per hour at the zone's perimeter.
Employers must ensure radiological surveillance of workers in radon zones or radiological safety zones and verify their exposure remains below dose levels specified in Article R. 4451-57 or below 6 millisieverts per 12 consecutive months for radon from soil.
Employers must define relevant individual dose constraints for workers based on foreseeable exposures, considering: (1) annual effective dose for regular activities in controlled or radon zones; (2) effective dose for intervention duration in colored controlled zones or during industrial radiology work; (3) equivalent dose for regular activities in extremity zones.
Employers must update dose constraints periodically within risk assessments and after any work method or condition changes affecting worker health and safety. For intervention-specific constraints, the radiation protection advisor must regularly verify that effective dose received complies with defined constraints.
When a radiation protection advisor identifies that a dose constraint contradicts the risk assessment, the advisor must inform the employer of this finding.